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Thuesen AD, Andersen H, Cardel M, Toft A, Walter S, Marcussen N,
Jensen BL, Bie P, Hansen PB. Differential effect of T-type voltage-gated
Ca2 channel disruption on renal plasma flow and glomerular filtration rate
in vivo. Am J Physiol Renal Physiol 307: F445–F452, 2014. First published
June 25, 2014; doi:10.1152/ajprenal.00016.2014.—Voltage-gated Ca2
(Cav) channels play an essential role in the regulation of renal blood
flow and glomerular filtration rate (GFR). Because T-type Cav chan-
nels are differentially expressed in pre- and postglomerular vessels, it
was hypothesized that they impact renal blood flow and GFR differ-
entially. The question was addressed with the use of two T-type Cav
knockout (Cav3.1/ and Cav3.2/) mouse strains. Continuous
recordings of blood pressure and heart rate, para-aminohippurate
clearance (renal plasma flow), and inulin clearance (GFR) were
performed in conscious, chronically catheterized, wild-type (WT) and
Cav3.1/ and Cav3.2/ mice. The contractility of afferent and
efferent arterioles was determined in isolated perfused blood vessels.
Efferent arterioles from Cav3.2/ mice constricted significantly
more in response to a depolarization compared with WT mice. GFR
was increased in Cav3.2/ mice with no significant changes in renal
plasma flow, heart rate, and blood pressure. Cav3.1/ mice had a
higher renal plasma flow compared with WT mice, whereas GFR was
indistinguishable from WT mice. No difference in the concentration
response to K was observed in isolated afferent and efferent arteri-
oles from Cav3.1/ mice compared with WT mice. Heart rate was
significantly lower in Cav3.1/ mice compared with WT mice with
no difference in blood pressure. T-type antagonists significantly in-
hibited the constriction of human intrarenal arteries in response to a
small depolarization. In conclusion, Cav3.2 channels support dilata-
tion of efferent arterioles and affect GFR, whereas Cav3.1 channels in
vivo contribute to renal vascular resistance. It is suggested that
endothelial and nerve localization of Cav3.2 and Cav3.1, respectively,
may account for the observed effects.
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THE REGULATION of renal blood flow, including renal medullary
blood flow, and glomerular filtration pressure involves voltage-
gated Ca2 (Cav) channels, which mediate changes in pre- and
postglomerular vessel diameters. These effects influence glo-
merular filtration rate (GFR) and salt and water homeostasis
and thereby blood pressure.
Cav channels are differentially expressed in the renal vascu-
lature, as preglomerular vessels express L-type (Cav1.2) and
T-type (Cav3.1 and Cav3.2) Ca2 channels, whereas postglo-
merular cortical efferent vessels are devoid of L-type Ca2
channels, but mouse efferent arterioles express T-type (Cav3.1
and Cav3.2) Ca2 channel subunits (17, 36). In contrast, both
L-type and T-type Ca2 channels are found in thick muscular
juxtamedullary efferent arterioles, which control medullary
perfusion (17).
The involvement of T-type Ca2 channels in the regulation
of microvascular diameter has been observed in both rat and
mouse afferent and efferent arterioles (12, 17, 35, 36), whereas
L-type Ca2 channels are assumed not to play a role in cortical
efferent arteriolar contractility (6, 17, 28, 31). Wheras mouse
studies have indicated a depolarization-induced effect in effer-
ent arterioles, results from rats are less clear. Some studies
have shown that Ca2 influx pathways in rat efferent vessels
are not dependent on depolarization for the ANG II-induced
contraction (24, 28, 29), whereas others have shown that the
T-type blockers mibefradil and nickel chloride affect the ANG
II-elicited constriction in efferent arterioles of the isolated
perfused hydronephrotic rat kidney model (21, 35). Moreover,
there appears to be regional differences in that juxtamedullary
arterioles (and vasa recta) exhibit a larger dependence on
depolarization compared with cortical efferent arterioles (17).
In vivo data from dogs treated with channel antagonists have
confirmed the heterogeneity between afferent and efferent
arterioles as well as an important contribution from T-type
Ca2 channels in efferent arterioles (23, 42). L-type antago-
nists led to an increased filtration fraction, corresponding to
dilatation of afferent but not efferent arterioles, whereas T-type
antagonists caused no increase in the filtration fraction (23) but
a similar increase in renal blood flow as L-type antagonists.
The contribution of T-type Ca2 channel activity to efferent
constriction is likely supported by the Cav3.1 subtype (36). The
Cav3.2 subtype is involved in nitric oxide (NO)-dependent
dilatation of efferent arterioles since Cav3.2 and endothelial
NO synthase (eNOS) blockade inhibited the secondary dilata-
tion after a depolarization-induced constriction of perfused
efferent arterioles (36). This is corroborated by the finding that
Cav3.2-deficient mice exhibit normal vasoconstrictor responses
in coronary arteries but reduced relaxation of coronary arteri-
oles after the administration of ACh and nitroprusside (8).
Based on these in vitro observations and the intrarenal vascular
distribution of Cav3 subtypes, it was hypothesized that disrup-
tion of Cav3.1 would increase renal blood flow but not alter
GFR proportionally since it is expressed both in pre- and
postglomerular vessels. On the other hand, targeting Cav3.2
would be predicted to increase vascular resistance and filtration
fraction due to its preferential efferent localization and NO-
promoting action in vitro.
Use of mice with targeted disruption of Cav channels allows
the investigation of the importance of T-type Ca2 channels
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without the question of drug specificity. To examine the
working hypotheses, we investigated renal function in con-
scious, unstressed freely moving mice that were deficient in
T-type Cav3.1 and Cav3.2 channels (Cav3.1/ and Cav3.2/
mice) by infusion of inulin and para-aminohippurate (PAH)
through chronic indwelling catheters.
MATERIALS AND METHODS
Animals. Experiments were conducted in Cav3.2/ mice and their
wild-type (WT) littermates (Cav3.2/ mice) obtained from heterozy-
gous breeding (Mutant Mouse Regional Resource Centers, Columbia,
MO). Mice were on a mixed 129 and C57BL/6J background. Further-
more, Cav3.1/ mice (27) and C57BL/6J WT mice (Taconic Farm,
Ry, Denmark) were used. C57BL/6J WT mice were used as controls
as Cav3.1/ mice were backcrossed to a C57BL/6J background for
10 generations. Animals were 8–10 wk of age and of both sexes.
The experimental protocol was approved by the Danish Animal
Experiments Inspectorate under the Danish Ministry of Food, Agri-
culture and Fisheries, and animal care followed guidelines of the
National Institutes of Health.
Human material. The use of human material was approved by the
Danish Ethical Committee, and kidney specimens were received from
the Department of Urology at Odense University Hospital (Odense,
Denmark). Renal blood vessels were isolated from patients who
underwent nephrectomy for renal cancer and had given their informed
written consent. Kidneys were extirpated, and intrarenal arteries
(interlobar and arcuate arteries) were isolated from normal tissue (18).
The study included 13 patients, with the primary diagnoses being
either malign or benign tumours. The age range was from 43–82 yr
old with a mean of 64  3.4 yr and blood pressure of 138  6.1/86 
4.2 mmHg.
Vascular responses and perfused mouse afferent and efferent
arterioles. Mice were killed by cervical dislocation. Cortical afferent
or efferent arterioles identified by appearance and location were
microdissected and perfused as previously described (2). In short, the
arteriole was transferred to a temperature-controlled (37°C) chamber
(Warner) containing DMEM-F-12 (saturated 5% CO2 in air) with
0.1% BSA. The segment was perfused by aspiration of the arteriole
into a holding pipette (tip diameter: 14 m) followed by cannulation
with a perfusion pipette (tip diameters: 5 m for efferent arterioles
and 7 m for afferent arterioles) and an increase in the driving pressure
until the vessel opened (20–30 mmHg). Experiments were performed
using an inverted microscope system (Olympus), and the luminal diam-
eter was measured at most reactive part of the arteriole determined at
the first response to high K. All measurements were made at the
same site of the arteriole. After the perfusion was established, all
experimental protocols started with a period of equilibration, and
vessel viability was tested by administration of high-K solution (100
mmol/l K) added to the bath. Concentration-response curves were
obtained for increasing concentrations of K in the range of 10, 15,
30, 55, and 75 mmol/l. Each concentration was applied for 3 min in
the presence of phentolamine (105 mol/l) to exclude nerve-mediated
-adrenergic effects of depolarization. Finally, the contractile re-
sponse to increasing concentrations of U-46619 and ANG II was
tested in afferent arterioles.
High-K solution contained (in mM) 45 NaCl, 70 KCl, 25
NaHCO3, 1.2 MgSO4, 2.5 K2HPO4, 1.3 CaCl2, 5.5 glucose, and 10
HEPES. Solutions were equilibrated with 5% CO2 in air, resulting in
pH 7.4 with 0.1% and 1% BSA superfusate and perfusate, respec-
tively.
Vascular responses and isometric force measurements in intrare-
nal human arteries. Human intrarenal arteries were isolated under a
stereomicroscope and stored at 4°C until the next day in the following
solution (in mmol/l): 103 NaCl, 5.4 KCl, 4.0 NaHCO3, 1.5 NaH2PO4,
0.8 MgSO4, 5.1 glucose, 0.9 Na-pyruvate, 30 Na-isethionic acid, and
5.6 HEPES 5.6 with added 10 ml/l MEM vitamin solution (M6895,
Sigma), 20 ml/l MEM essential amino acid solution (M5550, Sigma),
and 10 ml/l MEM nonessential amino acid solution (M7145, Sigma)
(18). Human intrarenal arteries were mounted in a Halpern-Mulvany
wire myograph (model 610, Danish Myo Technology, Aarhus, Den-
mark), and isometric force development was measured (PowerLab,
AD Instruments, Colorado Springs, CO). Artery rings were incubated
at 37°C in physiological salt solution, normalized, and allowed to
equilibrate for 30 min. The viability of vascular smooth muscle and
endothelial cells was tested by demonstrating contraction to phenyl-
ephrine (106 mol/l) and relaxation to ACh (106 mol/l), respec-
tively. In human intrarenal arteries, the contraction induced by in-
creasing concentrations of K (20, 40, 60, 80, and 100 mmol/l) was
tested in the absence and presence of the T-type blockers mibefradil
(107 mol/l) and NNC 55-0396 (3  106 mol/l, Sigma-Aldrich).
Each concentration of K was applied for 5 min in the presence of
phentolamin (105 mol/l).
Arterial blood pressure, heart rate, GFR, and renal plasma flow.
Mice were anesthetized (100 mg/kg ketamine and 10 mg/kg xylazine).
For measurements of arterial blood pressure and infusions of drugs,
catheters consisting of a micro-renathane tip connected to polyethyl-
ene tubing were placed in the femoral artery and vein, respectively,
and exteriorized through a subcutaneous tunnel from the groin to the
back of the neck (3, 16). In short, the catheters was filled with heparin
solution (100 IU/ml in isotonic glucose) and attached to a swivel,
enabling the mice to move freely. For analgesia, mice were given
subcutaneous injections of Temgesic [buprenorphinum (0.3 mg/ml,
3.75 mg/kg)]. Mice recovered for 5 days before continuous measure-
ments of mean arterial pressure (MAP) and heart rate (HR) for 4 days.
The arterial line was connected to a pressure transducer (Föhr Medical
Instruments, Hessen, Germany). Data were collected using LabView
software (National Instruments, Austin, TX).
GFR was measured based on a constant infusion of inulin (25).
Sinistrin [inutest (25%, 10 l/h)] was infused by connecting the
venous catheter to an infusion pump (Electronic shop, University of
Southern Denmark). The infusion lasted for 24 or 96 h to achieve
steady state, and a blood sample (100 l) was withdrawn from the
arterial catheter at both time points. The plasma inulin concentration
was determined by spectrophotometry with a modified version of the
method of Gabel et al. (13). The inulin concentration was quantified
by reaction by inulinase (Sigma-Aldrich). Inulin was hydrolyzed to
fructose, which was converted to sorbitol by sorbitol dehydrogenase.
The amount of NADH consumed in the process is proportional to the
amount of inulin in the sample. NADH concentrations were measured
by spectrophotometry at 340 nm (Versa Max microplate reader,
Molecular Devices). GFR was calculated as the inulin infusion rate
divided by the plasma inulin concentration.
In other experiments, PAH clearance was used as an estimate of
renal plasma flow. PAH (20% in saline, 10 l/h, Merck) was infused
continuously for 24 and 96 h, and two blood samples (100 l) was
taken at both time points. The experiment was repeated in WT mice
using 10% PAH in saline to verify that the tubular secretion maximum
was not reached. Blood samples were centrifuged, and plasma was
collected and stored at 80°C. PAH in plasma was measured by a
colorimetric reaction with dimethylaminocinnamaldehyde solution in
an acidic environment. The intensity of the color generated was
measured at 545 nm after 15–30 min of incubation. Renal plasma flow
was calculated as the PAH infusion rate divided by the plasma PAH
concentration at steady state, during which the infusion rate equals the
excretion rate.
Statistical analysis. Data are presented as means  SE. Signifi-
cance of changes was calculated by two-way ANOVA with a Bon-
ferroni reduction for multiple comparisons and Student’s t-test for
comparison of two groups. P values of 	0.05 were considered
significant.
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RESULTS
Cav3.2 mice. The contribution of Cav3.2 channels to baseline
renal hemodynamics was assessed by measurements in Cav3.2/
mice. GFR was significantly increased in Cav3.2/ mice com-
pared with Cav3.2/ mice after 24 h of infusion of inulin (Fig.
1A) by 37% with no significant difference between sexes. There
was no difference between inulin clearance measured after 24 and
96 h of infusion (data not shown). PAH clearance/renal plasma
flow was not significantly changed in Cav3.2/ mice compared
with WT mice (Fig. 1B). PAH clearances after 24 h of infusion
were 1.4  0.2 and 1.7  0.3 ml·min1·25 g mouse1 in
Cav3.2/ and Cav3.2/ mice, respectively, with no significant
difference between sexes. In control experiments, there was no
significant difference between renal plasma flows measured after
24 or 96 h of infusion or by infusion of 10% or 20% PAH at
identical rates, suggesting that a steady state was present and that
the tubular transport maximum was not reached by use of the
higher concentration (not shown).
MAPs and HRs measured over 4 days were not significantly
different between Cav3.2/ and Cav3.2/ mice (Fig. 1, C
and D), and there were also no significant differences in HR or
MAP between sexes (not shown).
The contractility of isolated arterioles was measured in re-
sponse to graded depolarization by K in Cav3.2/ and
Cav3.2/ mice. In afferent arterioles, the diameter averaged 8.1 
0.3 and 8.1 0.4 m in Cav3.2/ and Cav3.2/ mice, respec-
tively (n 
 6 in each series). The contractile response to increas-
ing concentrations of K in afferent arterioles revealed no signif-
icant difference in contractility between WT and Cav3.2/
animals, although a large a variance was observed in Cav3.2/
responses at low concentrations of K (Fig. 2A). Three of six
vessels constricted to 10 mmol/l K; however, this response
was not significant. K (30 mmol/l) induced a significant
constriction after 3 min of administration to afferent arterioles
from both Cav3.2/ and WT mice (Fig. 2B). Basal diameters
of efferent arterioles were not significantly different (7.3  0.3
m in Cav3.2/ mice and 7.0  0.3 m in Cav3.2/ mice,
n
 8). Depolarization-induced constrictions were significantly
larger in the absence of Cav3.2: the EC50 value for Cav3.2/
mice was 16 mmol/l compared with 31 mmol/l for Cav3.2/
mice (P	 0.05; Fig. 2C). K (30 mmol/l) induced a significant
constriction after 3 min of administration to efferent arterioles
from Cav3.2/ mice, whereas no significant constriction was
observed in WT mice (Fig. 2D).
Cav3.1 mice. The involvement of Cav3.1 in the regulation of
baseline renal perfusion and GFR was tested in Cav3.1/ and
WT mice. Values of GFR were not significantly different (Fig.
3A). However, renal plasma flow was significantly elevated
compared with WT mice (2.0 0.1 vs. 1.5 0.1 ml·min1·25 g
mouse1; Fig. 3B).
Resting basal MAPs averaged 105  4 and 104  3 mmHg
in WT and Cav3.1/ mice, respectively (n 
 6), with a
pronounced circadian rhythm in both genotypes (Fig. 4, A and
C); there was no significant difference between sexes. HRs in
WT and Cav3.1/ mice averaged 623  19 and 592  24
beats/min, respectively (Fig. 4, B and D). In male mice, HR
was attenuated significantly in Cav3.1/ mice compared with
WT mice. Female mice had significantly higher HRs than male
mice in both genotypes (Fig. 4D).
The increase in renal plasma flow could be due to a decrease
in vascular resistance in the afferent and/or efferent arteriole.
The possible contribution of Cav3.1 channels to arteriolar
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Fig. 1. Renal hemodynamics, mean arterial
pressure (MAP), and heart rate (HR) in
Cav3.2/ and Cav3.2/ mice. A: glomerular
filtration rate (GFR) was measured based on
inulin clearance using mice with chronically
indwelling catheters. *P 
 0.02. B: para-ami-
nohippuric acid (PAH) clearance was used as
an estimate of renal plasma flow (RPF). P 

0.44. C: MAP measured with indwelling cath-
eters for 4 days (D1–D4) and 3 nights (N1–
N3). D: HR measured over 4 days (D1–D4)
and 3 nights (N1–N3). Data are means  SE;
n 
 12 for inulin clearance and 7 for PAH
clearance.
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constriction was studied in isolated perfused vessels. Resting
basal diameters of efferent arterioles averaged 7.0  0.3 and
7.0 0.3 m in WT and Cav3.1/ mice, respectively (n
 8).
In afferent arterioles, diameters averaged 8.6  0.3 and 8.8 
0.5 m in WT and Cav3.1/ mice, respectively (n
 6). In all
experiments, the startup protocol with high-K solution elic-
ited a significant constriction that did not differ among the
genotypes. The experiment testing the response to increasing
concentrations of K on afferent arterioles revealed no differ-
ence in contractility between WT and Cav3.1/ animals, with
EC50 values of 30 mmol/l in WT animals and 24 mmol/l in
Cav3.1/ animals (Fig. 5A). K at 30 mmol/l mediated the
same degree of constriction in both Cav3.1/ and WT animals
(Fig. 5B). In efferent arterioles, eight individual experiments
testing the effect of K showed a concentration-dependent
constriction with EC50 values of 17 mmol/l in WT animals and
19 mmol/l in Cav3.1/ animals (Fig. 5C), showing no signif-
icant difference between WT and Cav3.1/ animals. The time
courses of the constriction in response to 30 mmol/l K were
indistinguishable (Fig. 5D).
Human arteries. The functional involvement of T-type Ca2
channels was tested in isolated human intrarenal arteries in a
myograph setting after depolarization. The K concentration
dependently contracted human intrarenal artery rings with an
EC50 value of 36 mmol/l. Administration of mibefradil in
concentrations specific for T-type Ca2 channels significantly
inhibited the contraction induced by 20 mmol/l K (Fig. 6A).
Another T-type antagonist, NNC 55-0396, also inhibited the
contraction significantly; however, this effect occurred at all
K concentrations (Fig. 6B).
DISCUSSION
The present results demonstrate markedly different renal
hemodynamic effects of absence of Cav3.2 or Cav3.1 at similar
average arterial blood pressure. The data support the conclu-
sion that Cav3.2 preferentially lowers resistance in the efferent
arteriole, thereby affecting GFR, as Cav3.2/ animals had
increased contractile responses of the efferent arteriole in
response to depolarization and increased GFR with no signif-
icant change in plasma flow. In contrast, deletion of Cav3.1
channels increased renal plasma flow, whereas GFR was not
changed measurably. That could be in agreement with an equal
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effect on the vasculature along afferent and efferent glomerular
arterioles, although that was not observed in isolated renal
arterioles in vitro. Notably, these changes occurred in the
absence of changes in systemic arterial blood pressure.
The present study shows that T-type Ca2 channels mediate
dilatation of renal postglomerular blood vessels as the constric-
tor response to depolarization was enhanced in efferent arteri-
oles from Cav3.2/ mice. There was no significant difference
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in contractility between afferent arterioles from WT and
knockout (KO) animals, although a transient constriction was
observed in some Cav3.2/ mice at the lowest K concen-
tration. This supports the suggestion that the T-type Ca2
channel subtype Cav3.2 mediates the secondary dilatation after
depolarization-induced constriction of the mouse perfused cor-
tical efferent arteriole (36). In agreement, inhibition of Cav3.2
by Ni2 at low concentrations potentiates the constriction by
changing it from a transient response to a sustained response.
Coronary blood vessels from Cav3.2/ mice show reduced
relaxation after administration of ACh and nitroprusside (8).
Furthermore, the dilatation of perfused efferent arterioles is
blocked by inhibition not only of Cav3.2 but also of eNOS,
suggesting that T-type Cav3.2 channels and NO release are
involved in the vasodilatation (36). The increased contractility
of efferent arterioles from Cav3.2/ mice could account for
the observed increase in GFR by elevating filtration pressure.
This would suggest that under normal physiological condi-
tions, Cav3.2 channels in postglomerular arterioles mediate a
dilatation that contributes to lower glomerular pressure. The
renal plasma flow was not significantly changed, and MAP was
not affected by lack of Cav3.2 channels. This is in agreement
with previous recordings of systolic blood pressure using tail
cuffs (10). Changes in blood pressure could therefore not
account for the increased GFR in KO animals. Furthermore,
HR was not different between genotypes, suggesting that it is
mainly Cav3.1 channels that are involved in regulating HR, as
observed in the present study and in a previous study by
Mangoni et al. (30).
For Cav3.1 channels, the present in vivo data are in agree-
ment with previous in vivo pharmacological data compatible
with important effects of T-type Ca2 channels on renal
hemodynamics. In anesthetized dogs, the T-type blocker mibe-
fradil increased renal blood flow with no significant effect on
GFR, suggesting balanced effects on afferent and efferent
arterioles, whereas L-type blockage (with nifedipine) increased
both renal plasma flow and GFR, suggesting a preferential
afferent effect. Similarly, in spontaneously hypertensive rats,
T-type blockade increased renal plasma flow more than GFR,
resulting in a decrease in the filtration fraction (43). The
increase in renal blood flow without an increase in GFR in
response to T-type blockade has been suggested to be due to
dilatation of the efferent arteriole. An in vivo study (23) using
a camera probe inserted directly into the kidney revealed a
relative dilation of the efferent arteriole larger than that of the
afferent arteriole after administration of the T-type antagonist
mibefradil, and, in agreement, T-type antagonists have been
demonstrated to dilate efferent arterioles in vitro (4, 20, 21, 35,
36). However, in the present study, K-induced contractility
responses of afferent and efferent arterioles of Cav3.1/ mice
were not significantly different compared with WT mice. This
is in disagreement with previous pharmacological studies (15,
22) showing an effect of a T-type blocker on arteriolar con-
tractility.
The different responses in vivo with increased renal blood
flow in Cav3.1/ mice with no apparent contribution of
Cav3.1 in vitro in afferent arterioles could also be due to an
attenuated sympathetic efferent nerve traffic that involves T-
type Ca2 channels. Chen and coworkers (7) investigated
central sympathetic activity and T-type Ca2 channels in a
preparation of brain stem-spinal cord-splanchnic sympathetic
nerves. They demonstrated that Cav3.2 channels were required
for maintaining central sympathetic outflow, and Cav3.1 had an
inhibitory effect (7). In a clinical study (19), the T-type
antagonist efonidipine reduced HR and sympathetic nervous
activity. Renal nerve activity was not measured directly in
Cav3.1/ animals, but since Cav3.1/ male mice displayed a
lower HR, this would be compatible with attenuated sympa-
thetic drive, although impaired automaticity in the sinus node
also might be involved.
Furthermore, the in vivo data could be affected by a changed
hormonal status as T-type blockers are involved in aldosterone
release (9, 37) and the T-type antagonist efonidipine lowers
aldosterone plasma levels in humans (34). The aldosterone
level in KO mice could therefore be expected to be lowered in
KO animals. However, a potential lower aldosterone level is
less likely as the reason for the observed increased GFR.
Both T-type Ca2 channels (Cav3.1 and Cav3.2) have been
shown to be expressed in renal glomerular vessels (17). In
contrast to the expression data, a recent study (40) found no
T-type Ca2 currents in either afferent or efferent arteriole
myocytes, but T-type Ca2 currents were detected in tail
arteries. T-type Ca2 currents have previously been measured
in preglomerular vascular smooth muscle cells (14). However,
this discrepancy might be explained by the heterogeneous
population of cells described by Gordienko et al. (14).
Ca2 blockers remain a popular first choice drug in the
treatment of essential hypertension; however, the selectivity
for different Ca2 channels differs, with some drugs affecting
both L- and T-type Ca2 channels and others affecting only
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Fig. 6. Depolarization-induced constriction in
human intrarenal arteries. A: effect of T-type
Cav channel inhibition by mibefradil on K-
induced dose-response contractions in human
intrarenal blood vessels (n 
 7). B: effect of
NNC 55-0396 (NNC; T-type blocker) on K-
induced dose-response contractions in human
intrarenal arteries (n 
 6). All data are means 
SE. *P  0.001; **P  0.01; ***P  0.05.
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L-type Ca2 channels. Combined T- and L-type blockers have
been suggested to have a therapeutic advantage over selective
L-type blockers by providing renoprotection due to differential
expression of Ca2 channels, with only T-type Ca2 channels
(Cav3.1 and Cav3.2) expressed in efferent arterioles (15, 22,
42). Clinical data support a renoprotective effect of combined
T- and L-type blockers as it was concluded that treatment with
a combined L- and T-type antagonist yields greater efficacy
that a L-type antagonist in reducing blood pressure and pro-
teinuria (32, 33, 38). The Amlodipine-to-Benidipine Change-
over study showed that benidipine (a combined L- and T-type
antagonist) caused a larger reduction in blood pressure and
proteinuria compared with L-type treatment by amlodipine
(32), suggesting a vasoconstrictor effect of T-type Ca2 chan-
nels on efferent arterioles. The present data show that it is
imperative to discriminate between the effects of Cav3.1 and
Cav3.2 since selective abrogated function of Cav3.2 leads to
increased GFR. Therefore, antagonists with a Cav3.2 prefer-
ence are less likely to mediate a renoprotective effect. The
renoprotective effect of combined blockers in clinical studies
could be due to a preferential action on Cav3.1, since an
increased renal plasma flow and a tendency to decreased GFR
was found in the absence of Cav3.1 channels in mice. T-type
Ca2 channels are present in human resistance blood vessels (18).
The present study using pharmacological inhibitors shows
that T-type Ca2 channels play a significant role in contractil-
ity of human intrarenal arteries. Increased tension at low K
concentrations was significantly inhibited after both mibefradil
and NNC 55-0396. This implies a graded contribution of Cav
channels with T-type effects at small deviations from the
resting membrane potential. This is in agreement a recent study
in T-type KO mice (5) and in a pharmacological study (1)
showing the involvement of T-type Ca2 channels in response
to small increases in perfusion pressure, which concluded that
T-type Ca2 channels do play a role in the myogenic response
(5). In contrast to the present results with mibefradil, NNC
55-0396 inhibited the contraction induced at all K concen-
trations, which could be due to variations between patients or,
more likely, that the drug also affects L-type Ca2 channels, as
previously suggested (26). Furthermore, an altered function of
kidney vascular segments occurs in several pathological con-
ditions, such as diabetes and hypertension (11, 39). The present
confirmation of a functional role for T-type Ca2 channels in
the regulation of renal function suggests that T-type Ca2
channels could play a role under physiological conditions as
well as in pathophysiological situations.
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